HZHonghai Zhang

Honghai Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Honghai Zhang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Zhang

    Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, USA

    2 shared publications
  • Chun-Wei Chen

    Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, USA

    2 shared publications
  • Hanjun Qin

    10The Integrative Genomics Core, Beckman Research Institute of City of Hope, Duarte, CA

    2 shared publications
  • James C. Mulloy

    12Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    2 shared publications
  • Jianjun Chen

    Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, USA

    2 shared publications
  • Lei Dong

    Quantitative Biomedical Research Center, Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, USA

    2 shared publications

Latest Publications

  • Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

    by Lili Ren, Honghai Zhang, Olga Bobileva, Francesco Nai, Hongjie Bi, Anthony Chan, Genevieve E. Baker, Lei Dong, David Guarin, Weidong Hu, et al.

    N7-methylguanosine (m7G), a prevalent modification in transfer RNAs (tRNAs), is primarily catalyzed by the methyltransferase METTL1. Although growing evidence supports a role for METTL1 in various tumors, its therapeutic potential and precise function in leukemia stem cell (LSC) homeostasis remain largely unexplored. Here, we identify METTL1 as a key regulator of LSC self-renewal and homing within bone marrow (BM) microenvironment through catalyzing m7G formation on a specific tRNA, tRNAPheGAA, thereby promoting leukemogenesis. Mechanistically, METTL1 loss significantly reduces m7G abundance and steady-state levels of tRNAPheGAA, leading to translation suppression and degradation of transcripts enriched with tRNAPheGAA-related codons, such as hematopoietic cell kinase (HCK). Decreased HCK expression disrupts CXCR4 signaling, impairing LSC self-renewal and BM homing. Therapeutically, we characterized a small-molecule METTL1 inhibitor (M1i; NSC137443), through high-throughput screening. Pharmacological inhibition of METTL1 demonstrated potent antitumor efficacy by reducing tRNA m7G levels and disrupting the tRNAPheGAA/HCK/CXCR4 cascade. Notably, targeting METTL1 significantly reduces LSC frequency, delays leukemogenesis, and prolongs survival in multiple acute myeloid leukemia models. Together, our findings establish a previously unrecognized role for METTL1 and its target tRNAPheGAA in LSC homeostasis and provide compelling proof-of-concept evidence that METTL1 is a druggable epitranscriptomic target for antileukemia therapy.


  • Open Access

    DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance

    by Hongjie Bi, Wei Li, Lili Ren, Honghai Zhang, Lei Dong, Anthony Chan, Xueer Wang, Lu Yang, Xiaoxu Zhang, Meilin Xue, et al.

    Stress granules (SGs) and processing bodies (PBs), assembled via liquid-liquid phase separation (LLPS), are critical for spatial regulation of gene expression in the cytoplasm. However, their roles in tumorigenesis remain poorly understood. Here, we show DEAD-box helicase 6 (DDX6) as the most promising vulnerability in acute myeloid leukemia (AML) through in vitro and in vivo CRISPR screenings using a specialized library targeting RNA-binding proteins enriched in SGs and PBs. Knockout (KO) of DDX6 significantly delays leukemogenesis with minimal impact on normal hematopoiesis. Importantly, the functions of DDX6 in AML depend largely on its ability to trigger LLPS and PB assembly. Mechanistically, PBs serve as “reservoirs” for the mRNAs interacting directly with DDX6 and having low GC content. DDX6 KO leads to rapid PB dissolution and release of PB-enriched mRNAs, such as BCAT1, into the cytosol, where these transcripts undergo degradation. By reducing BCAT1 levels, DDX6 KO reprograms amino acid metabolism and sensitizes AML cells to cytarabine chemotherapy.